Orphan Drug Focus RareMoon specializes in regulatory support for orphan drugs and advanced therapies, presenting a clear entry point for BD outreach to biotech firms pursuing rare disease programs needing regulatory strategy, dossiers, and global submissions.

Strategic Partnerships Recent joint consulting packages with Franklin Biolabs signal a willingness to collaborate on preclinical-to-clinical transitions, suggesting opportunities to propose bundled regulatory services with CRO partnerships or co-sell arrangements.

Global Regulatory Expertise With over 300 years of combined regulatory experience and a track record of global agency interactions, there is a compelling value proposition for mid-size biotech companies seeking to de-risk international regulatory pathways for orphan/advanced therapies.

Growth and Accessibility Positioning regulations as a runway to patient access indicates potential to upsell end-to-end regulatory programs that integrate CMC, nonclinical, and clinical strategies, appealing to companies aiming for faster regulatory milestones.

Startup to Scale The small team size (2-10 employees) combined with revenue in the mid-market range points to opportunities for scalable, advisory-led engagements, resume-friendly for smaller biotech firms before major CRO partnerships.